1
|
Jiang Z, Liu X, Yuan Z, He H, Wang J, Zhang X, Gong Z, Hou L, Shen L, Guo F, Zhang J, Wang J, Xu D, Liu Z, Li H, Chen X, Long C, Li J, Chen S. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. ACS Med Chem Lett 2019; 10:1068-1073. [PMID: 31312410 PMCID: PMC6627728 DOI: 10.1021/acsmedchemlett.9b00189] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Accepted: 06/24/2019] [Indexed: 12/13/2022] Open
Abstract
A novel peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist 5c was developed with an EC50 of 8 nM for PPARα, 5 nM for PPARδ, and >300-fold selectivity against PPARγ (EC50 = 2939 nM), respectively. Further ADME and pharmacokinetic studies indicated 5c possessed distinguished in vitro and in vivo profiles. The excellent in vivo efficacy of compound 5c was demonstrated by the rat primary biliary cirrhosis (PBC) model.
Collapse
Affiliation(s)
- Zhigan Jiang
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Xing Liu
- R&D
Center, Guangdong Zhongsheng Pharmaceutical
Co., Ltd. The Information
Area of Xihu Industrial Base, Shilong Town, Dongguan, Guangdong Province 523325, P. R. China
| | - Zhiliang Yuan
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Haiying He
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Jing Wang
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Xiao Zhang
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Zhen Gong
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Lijuan Hou
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Liang Shen
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Fengxun Guo
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Jiliang Zhang
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Jianhua Wang
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Deming Xu
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Zhuowei Liu
- R&D
Center, Guangdong Zhongsheng Pharmaceutical
Co., Ltd. The Information
Area of Xihu Industrial Base, Shilong Town, Dongguan, Guangdong Province 523325, P. R. China
- Guangdong
Raynovent Biotech Co., Ltd., Room 1701-1705, Main Building of Rongyi Tower, No. 5, Xinxi Road,
SongShan Lake Hi-tech Industrial Development Zone, Dongguan, Guangdong Province 523808, P. R. China
| | - Haijun Li
- R&D
Center, Guangdong Zhongsheng Pharmaceutical
Co., Ltd. The Information
Area of Xihu Industrial Base, Shilong Town, Dongguan, Guangdong Province 523325, P. R. China
- Guangdong
Raynovent Biotech Co., Ltd., Room 1701-1705, Main Building of Rongyi Tower, No. 5, Xinxi Road,
SongShan Lake Hi-tech Industrial Development Zone, Dongguan, Guangdong Province 523808, P. R. China
| | - Xiaoxin Chen
- R&D
Center, Guangdong Zhongsheng Pharmaceutical
Co., Ltd. The Information
Area of Xihu Industrial Base, Shilong Town, Dongguan, Guangdong Province 523325, P. R. China
- Guangdong
Raynovent Biotech Co., Ltd., Room 1701-1705, Main Building of Rongyi Tower, No. 5, Xinxi Road,
SongShan Lake Hi-tech Industrial Development Zone, Dongguan, Guangdong Province 523808, P. R. China
| | - Chaofeng Long
- R&D
Center, Guangdong Zhongsheng Pharmaceutical
Co., Ltd. The Information
Area of Xihu Industrial Base, Shilong Town, Dongguan, Guangdong Province 523325, P. R. China
- Guangdong
Raynovent Biotech Co., Ltd., Room 1701-1705, Main Building of Rongyi Tower, No. 5, Xinxi Road,
SongShan Lake Hi-tech Industrial Development Zone, Dongguan, Guangdong Province 523808, P. R. China
| | - Jian Li
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| | - Shuhui Chen
- WuXi AppTec (Shanghai)
Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China
| |
Collapse
|
2
|
Fang J, Peng Z, Yang Y, Wang J, Guo J, Gong H. Graphene-Oxide-Promoted Direct Dehydrogenative Coupling Reaction of Aromatics. ASIAN J ORG CHEM 2018. [DOI: 10.1002/ajoc.201700673] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Jingxian Fang
- Key Laboratory for Green Organic Synthesis and Application of Hunan Province; The Key Laboratory of Environmentally Friendly Chemistry and Application of the Ministry of Education, College of Chemistry; Xiangtan University; Xiangtan 411105 P. R. China
| | - Zhiyong Peng
- Chengda Pharmaceuticals Co., Ltd.; Huanghe Road 36, Economic Development Zone, Jiashan Zhejiang 314100 P. R. China
| | - Yun Yang
- Key Laboratory for Green Organic Synthesis and Application of Hunan Province; The Key Laboratory of Environmentally Friendly Chemistry and Application of the Ministry of Education, College of Chemistry; Xiangtan University; Xiangtan 411105 P. R. China
| | - Jiawei Wang
- Key Laboratory for Green Organic Synthesis and Application of Hunan Province; The Key Laboratory of Environmentally Friendly Chemistry and Application of the Ministry of Education, College of Chemistry; Xiangtan University; Xiangtan 411105 P. R. China
| | - Jiaying Guo
- Key Laboratory for Green Organic Synthesis and Application of Hunan Province; The Key Laboratory of Environmentally Friendly Chemistry and Application of the Ministry of Education, College of Chemistry; Xiangtan University; Xiangtan 411105 P. R. China
| | - Hang Gong
- Key Laboratory for Green Organic Synthesis and Application of Hunan Province; The Key Laboratory of Environmentally Friendly Chemistry and Application of the Ministry of Education, College of Chemistry; Xiangtan University; Xiangtan 411105 P. R. China
| |
Collapse
|
3
|
Yang F, Xie F, Zhang Y, Xia Y, Liu W, Jiang F, Lam C, Qiao Y, Xie D, Li J, Fu L. Y-shaped bis-arylethenesulfonic acid esters: Potential potent and membrane permeable protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2017; 27:2166-2170. [DOI: 10.1016/j.bmcl.2017.03.060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 03/07/2017] [Accepted: 03/22/2017] [Indexed: 12/31/2022]
|
4
|
The design strategy of selective PTP1B inhibitors over TCPTP. Bioorg Med Chem 2016; 24:3343-52. [PMID: 27353889 DOI: 10.1016/j.bmc.2016.06.035] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 06/16/2016] [Accepted: 06/17/2016] [Indexed: 02/01/2023]
Abstract
Protein tyrosine phosphatase 1B (PTP1B) has already been well studied as a highly validated therapeutic target for diabetes and obesity. However, the lack of selectivity limited further studies and clinical applications of PTP1B inhibitors, especially over T-cell protein tyrosine phosphatase (TCPTP). In this review, we enumerate the published specific inhibitors of PTP1B, discuss the structure-activity relationships by analysis of their X-ray structures or docking results, and summarize the characteristic of selectivity related residues and groups. Furthermore, the design strategy of selective PTP1B inhibitors over TCPTP is also proposed. We hope our work could provide an effective way to gain specific PTP1B inhibitors.
Collapse
|
5
|
Abstract
SIGNIFICANCE Protein tyrosine phosphatases (PTPs) are important enzymes that are involved in the regulation of cellular signaling. Evidence accumulated over the years has indicated that PTPs present exciting opportunities for drug discovery against diseases such as diabetes, cancer, autoimmune diseases, and tuberculosis. However, the highly conserved and partially positive charge of the catalytic sites of PTPs is a major challenge in the development of potent and highly selective PTP inhibitors. RECENT ADVANCES Here, we examine the strategy of developing bidentate inhibitors for selective inhibition of PTPs. Bidentate inhibitors are small-molecular-weight compounds with the ability to bind to both the active site and a non-conserved secondary phosphate binding site. This secondary phosphate binding site was initially discovered in protein tyrosine phosphatase 1B (PTP1B), and, hence, most of the bidentate inhibitors reported in this review are PTP1B inhibitors. CRITICAL ISSUES Although bidentate inhibition is a good strategy for developing potent and selective inhibitors, the cell membrane permeability and pharmacokinetic properties of the inhibitors are also important for successful drug development. In this review, we will also summarize the various efforts made toward the development of phosphotyrosine (pTyr) mimetics for increasing cellular permeability. FUTURE DIRECTIONS Even though the secondary phosphate binding site was initially found in PTP1B, structural data have shown that a secondary binding site can also be found in other PTPs, albeit with varying degrees of accessibility. Along with improvements in pTyr mimetics, we believe that the future will see an increase in the number of orally bioavailable bidentate inhibitors against the various classes of PTPs.
Collapse
Affiliation(s)
- Joo-Leng Low
- 1 Institute of Chemical and Engineering Sciences , Agency for Science Technology and Research, Singapore, Singapore
| | | | | |
Collapse
|
6
|
Lountos GT, Tropea JE, Waugh DS. Structure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas' disease. Mol Biochem Parasitol 2013; 187:1-8. [PMID: 23137716 PMCID: PMC4197799 DOI: 10.1016/j.molbiopara.2012.10.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Revised: 10/22/2012] [Accepted: 10/26/2012] [Indexed: 12/26/2022]
Abstract
Chagas' disease, a neglected tropical affliction transmitted by the flagellated protozoan Trypanosoma cruzi, is prevalent in Latin America and affects nearly 18 million people worldwide, yet few approved drugs are available to treat the disease. Moreover, the currently available drugs exhibit severe toxicity or are poorly effective in the chronic phase of the disease. This limitation, along with the large population at risk, underscores the urgent need to discover new molecular targets and novel therapeutic agents. Recently, the T. cruzi protein tyrosine phosphatase TcPTP1 has been implicated in the cellular differentiation and infectivity of the parasite and is therefore a promising target for the design of novel anti-parasitic drugs. Here, we report the X-ray crystal structure of TcPTP1 refined to a resolution of 2.18 Å, which provides structural insights into the active site environment that can be used to initiate structure-based drug design efforts to develop specific TcPTP1 inhibitors. Potential strategies to develop such inhibitors are also discussed.
Collapse
Affiliation(s)
- George T. Lountos
- Basic Science Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
- Macromolecular Crystallography Laboratory, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - Joseph E. Tropea
- Macromolecular Crystallography Laboratory, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - David S. Waugh
- Macromolecular Crystallography Laboratory, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| |
Collapse
|
7
|
Inhibitors of the Yersinia protein tyrosine phosphatase through high throughput and virtual screening approaches. Bioorg Med Chem Lett 2012; 23:1056-62. [PMID: 23294700 DOI: 10.1016/j.bmcl.2012.12.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Revised: 12/04/2012] [Accepted: 12/10/2012] [Indexed: 02/02/2023]
Abstract
The bacterial protein tyrosine phosphatase YopH is an essential virulence determinant in Yersinia pestis and a potential antibacterial drug target. Here we report our studies of screening for small molecule inhibitors of YopH using both high throughput and in silico approaches. The identified inhibitors represent a diversity of chemotypes and novel pTyr mimetics, providing a starting point for further development and fragment-based design of multi-site binding inhibitors. We demonstrate that the applications of high throughput and virtual screening, when guided by structural binding mode analysis, is an effective approach for identifying potent and selective inhibitors of YopH and other protein phosphatases for rational drug design.
Collapse
|
8
|
Lignopurines: A new family of hybrids between cyclolignans and purines. Synthesis and biological evaluation. Eur J Med Chem 2012; 58:377-89. [DOI: 10.1016/j.ejmech.2012.10.026] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Revised: 10/15/2012] [Accepted: 10/16/2012] [Indexed: 11/22/2022]
|
9
|
Lee HJ, Xin H, Park SM, Park SI, Ahn T, Park DK, Jenekhe SA, Kwon TW. Synthesis and Properties of Diarylamino-Substituted Linear and Dendritic Oligoquinolines for Organic Light-Emitting Diodes. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.5.1627] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
10
|
Kim SE, Bahta M, Lountos GT, Ulrich RG, Burke TR, Waugh DS. Isothiazolidinone (IZD) as a phosphoryl mimetic in inhibitors of the Yersinia pestis protein tyrosine phosphatase YopH. ACTA CRYSTALLOGRAPHICA. SECTION D, BIOLOGICAL CRYSTALLOGRAPHY 2011; 67:639-45. [PMID: 21697602 PMCID: PMC3121299 DOI: 10.1107/s0907444911018610] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2011] [Accepted: 05/16/2011] [Indexed: 11/10/2022]
Abstract
Isothiazolidinone (IZD) heterocycles can act as effective components of protein tyrosine phosphatase (PTP) inhibitors by simultaneously replicating the binding interactions of both a phosphoryl group and a highly conserved water molecule, as exemplified by the structures of several PTP1B-inhibitor complexes. In the first unambiguous demonstration of IZD interactions with a PTP other than PTP1B, it is shown by X-ray crystallography that the IZD motif binds within the catalytic site of the Yersinia pestis PTP YopH by similarly displacing a highly conserved water molecule. It is also shown that IZD-based bidentate ligands can inhibit YopH in a nonpromiscuous fashion at low micromolar concentrations. Hence, the IZD moiety may represent a useful starting point for the development of YopH inhibitors.
Collapse
Affiliation(s)
- Sung-Eun Kim
- Chemical Biology Laboratory, National Cancer Institute at Frederick, PO Box B, Frederick, MD 21702-1201, USA
| | - Medhanit Bahta
- Chemical Biology Laboratory, National Cancer Institute at Frederick, PO Box B, Frederick, MD 21702-1201, USA
| | - George T. Lountos
- Macromolecular Crystallography Laboratory, National Cancer Institute at Frederick, PO Box B, Frederick, MD 21702-1201, USA
| | - Robert G. Ulrich
- Laboratory of Molecular Immunology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
| | - Terrence R. Burke
- Chemical Biology Laboratory, National Cancer Institute at Frederick, PO Box B, Frederick, MD 21702-1201, USA
| | - David S. Waugh
- Macromolecular Crystallography Laboratory, National Cancer Institute at Frederick, PO Box B, Frederick, MD 21702-1201, USA
| |
Collapse
|
11
|
Bahta M, Lountos GT, Dyas B, Kim SE, Ulrich RG, Waugh DS, Burke TR. Utilization of nitrophenylphosphates and oxime-based ligation for the development of nanomolar affinity inhibitors of the Yersinia pestis outer protein H (YopH) phosphatase. J Med Chem 2011; 54:2933-43. [PMID: 21443195 PMCID: PMC3085962 DOI: 10.1021/jm200022g] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Our current study reports the first K(M) optimization of a library of nitrophenylphosphate-containing substrates for generating an inhibitor lead against the Yersinia pestis outer protein phosphatase (YopH). A high activity substrate identified by this method (K(M) = 80 μM) was converted from a substrate into an inhibitor by replacement of its phosphate group with difluoromethylphosphonic acid and by attachment of an aminooxy handle for further structural optimization by oxime ligation. A cocrystal structure of this aminooxy-containing platform in complex with YopH allowed the identification of a conserved water molecule proximal to the aminooxy group that was subsequently employed for the design of furanyl-based oxime derivatives. By this process, a potent (IC(50) = 190 nM) and nonpromiscuous inhibitor was developed with good YopH selectivity relative to a panel of phosphatases. The inhibitor showed significant inhibition of intracellular Y. pestis replication at a noncytotoxic concentration. The current work presents general approaches to PTP inhibitor development that may be useful beyond YopH.
Collapse
Affiliation(s)
- Medhanit Bahta
- Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, U.S.A
| | - George T. Lountos
- Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, U.S.A
| | - Beverly Dyas
- Laboratory of Molecular Immunology, United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, U.S.A
| | - Sung-Eun Kim
- Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, U.S.A
| | - Robert G. Ulrich
- Laboratory of Molecular Immunology, United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, U.S.A
| | - David S. Waugh
- Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, U.S.A
| | - Terrence R. Burke
- Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, U.S.A
| |
Collapse
|
12
|
Comeau AB, Critton DA, Page R, Seto CT. A Focused Library of Protein Tyrosine Phosphatase Inhibitors. J Med Chem 2010; 53:6768-72. [DOI: 10.1021/jm100528p] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Anthony B. Comeau
- Department of Chemistry, Brown University, 324 Brook Street, Box H, Providence, Rhode Island 02912
| | - David A. Critton
- Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Box G-E4, Providence, Rhode Island 02912
| | - Rebecca Page
- Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Box G-E4, Providence, Rhode Island 02912
| | - Christopher T. Seto
- Department of Chemistry, Brown University, 324 Brook Street, Box H, Providence, Rhode Island 02912
| |
Collapse
|
13
|
Liu F, Hakami RM, Dyas B, Bahta M, Lountos GT, Waugh DS, Ulrich RG, Burke TR. A rapid oxime linker-based library approach to identification of bivalent inhibitors of the Yersinia pestis protein-tyrosine phosphatase, YopH. Bioorg Med Chem Lett 2010; 20:2813-6. [PMID: 20350805 DOI: 10.1016/j.bmcl.2010.03.058] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2010] [Revised: 03/10/2010] [Accepted: 03/11/2010] [Indexed: 10/19/2022]
Abstract
A bivalent tethered approach toward YopH inhibitor development is presented that joins aldehydes with mixtures of bis-aminooxy-containing linkers using oxime coupling. The methodology is characterized by its facility and ease of use and its ability to rapidly identify low micromolar affinity inhibitors. The generality of the approach may potentially make it amenable to the development of bivalent inhibitors directed against other phosphatases.
Collapse
Affiliation(s)
- Fa Liu
- Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, USA
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Vovk AI, Kononets LA, Tanchuk VY, Cherenok SO, Drapailo AB, Kalchenko VI, Kukhar VP. Inhibition of Yersinia protein tyrosine phosphatase by phosphonate derivatives of calixarenes. Bioorg Med Chem Lett 2010; 20:483-7. [DOI: 10.1016/j.bmcl.2009.11.126] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2009] [Revised: 11/20/2009] [Accepted: 11/21/2009] [Indexed: 01/22/2023]
|
15
|
Le Quement ST, Nielsen TE, Meldal M. Divergent Pathway for the Solid-Phase Conversion of Aromatic Acetylenes to Carboxylic Acids, α-Ketocarboxylic Acids, and Methyl Ketones. ACTA ACUST UNITED AC 2008; 10:546-56. [DOI: 10.1021/cc8000037] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - Thomas E. Nielsen
- Carlsberg Laboratory, SPOCC Centre, Gamle Carlsberg Vej 10, DK-2500 Valby, Denmark
| | - Morten Meldal
- Carlsberg Laboratory, SPOCC Centre, Gamle Carlsberg Vej 10, DK-2500 Valby, Denmark
| |
Collapse
|
16
|
Maccari R, Paoli P, Ottanà R, Jacomelli M, Ciurleo R, Manao G, Steindl T, Langer T, Vigorita MG, Camici G. 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 2007; 15:5137-49. [PMID: 17543532 DOI: 10.1016/j.bmc.2007.05.027] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2006] [Revised: 05/04/2007] [Accepted: 05/11/2007] [Indexed: 11/20/2022]
Abstract
4-(5-Arylidene-2,4-dioxothiazolidin-3-yl)methylbenzoic acids (2) were synthesized and evaluated in vitro as inhibitors of PTP1B and LMW-PTP, two protein tyrosine phosphatases (PTPs) which act as negative regulators of the metabolic and mitotic signalling of insulin. The synthesis of compounds 2 represents an example of utilizing phosphotyrosine-mimetics to identify effective low molecular weight nonphosphorus inhibitors of PTPs. Several thiazolidinediones 2 exhibited PTP1B inhibitory activity in the low micromolar range with moderate selectivity for human PTP1B and IF1 isoform of human LMW-PTP compared with other related PTPs.
Collapse
Affiliation(s)
- Rosanna Maccari
- Dipartimento Farmaco-Chimico, Università di Messina, Vl SS Annunziata, Messina, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Xie J, Seto CT. A two stage click-based library of protein tyrosine phosphatase inhibitors. Bioorg Med Chem 2006; 15:458-73. [PMID: 17046267 PMCID: PMC1764825 DOI: 10.1016/j.bmc.2006.09.036] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2006] [Revised: 09/18/2006] [Accepted: 09/20/2006] [Indexed: 01/20/2023]
Abstract
Protein tyrosine phosphatases (PTPs) are important regulators of signal transduction pathways. Potent and selective PTP inhibitors are useful for probing these pathways and also may serve as drugs for the treatment of a variety of diseases including type 2 diabetes and infection by the bacterium Yersinia pestis. In this report Cu(I)-catalyzed 'click' cycloaddition reactions between azides and alkynes were employed to generate two sequential libraries of PTP inhibitors. In the first round library methyl 4-azidobenzoylformate was reacted with 56 mono- and diynes. After hydrolysis of the methyl esters, the resulting alpha-ketocarboxylic acids were assayed in crude form against the Yersinia PTP and PTP1B. Four compounds were selected for further evaluation, and one compound was chosen as the lead for generation of the second round library. This lead compound was modified by conversion of an alcohol into an azide group, and the resulting azide was reacted with the same 56 mono- and diynes that were used in the first generation library. After screening the crude inhibitors against the Yersinia PTP and PTP1B, four compounds were selected and evaluated in pure form against the Yersinia PTP, PTP1B, TCPTP, LAR, and CD45. The best bis(alpha-ketocarboxylic acid) inhibitor 34 had an IC(50) value of 550nM against the Yersinia PTP and an IC(50) value of 710nM against TCPTP. The most potent inhibitor containing a single alpha-ketocarboxylic acid group 32 had IC(50) values of 2.1, 5.7, and 2.6 microM against the Yersinia PTP, PTP1B, and TCPTP, respectively.
Collapse
Affiliation(s)
| | - Christopher T. Seto
- *Department of Chemistry, Brown University, 324 Brook St. Box H, Providence, Rhode Island 02912, Phone: 401-863-3587; Fax: 401-863-9368,
| |
Collapse
|
18
|
Liu GX, Tan JZ, Niu CY, Shen JH, Luo XM, Shen X, Chen KX, Jiang HL. Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor. Acta Pharmacol Sin 2006; 27:100-10. [PMID: 16364216 DOI: 10.1111/j.1745-7254.2006.00251.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
AIM To investigate the dynamic properties of protein-tyrosine phosphatase (PTP) 1B and reveal the structural factors responsible for the high inhibitory potency and selectivity of the inhibitor SNA for PTP1B. METHODS We performed molecular dynamics (MD) simulations using a long time-scale for both PTP1B and PTP1B complexed with the inhibitor SNA, the most potent and selective PTP1B inhibitor reported to date. The trajectories were analyzed by using principal component analysis. RESULTS Trajectory analyses showed that upon binding the ligand, the flexibility of the entire PTP1B molecule decreases. The most notable change is the movement of the WPD-loop. Our simulation results also indicated that electrostatic interactions contribute more to PTP1B-SNA complex conformation than the van der Waals interactions, and that Lys41, Arg47, and Asp48 play important roles in determining the conformation of the inhibitor SNA and in the potency and selectivity of the inhibitor. Of these, Arg47 contributed most. These results were in agreement with previous experimental results. CONCLUSION The information presented here suggests that potent and selective PTP1B inhibitors can be designed by targeting the surface residues, for example the region containing Lys41, Arg47, and Asp48, instead of the second phosphate binding site (besides the active phosphate binding site).
Collapse
Affiliation(s)
- Gui-xia Liu
- Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China.
| | | | | | | | | | | | | | | |
Collapse
|